Các Ảnh Hưởng Tiềm Tàng Của Liệu Pháp Bổ Sung Đối Với Biến Chứng Vận Động Và Không Vận Động Trong Bệnh Parkinson

Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the “common” neurologic disorders? Neurology 2007 Jan 30; 68(5): 326–37 Bhidayasiri R, Truong DD. Motor complications in Parkinson disease: clinical manifestations and management. J Neurol Sci 2008 Mar 15; 266(1–2): 204–15 Truong DD, Bhidayasiri R, Wolters E. Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci 2008 Mar 15; 266(1–2): 216–28 Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson’s disease: an update. Clin Pharmacokinet 2006 Feb; 45(2): 109–36 Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002; 41(4): 261–309 Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000 Oct 18; 284(15): 1931–8 Rascol O, Brooks DJ, Korczyn AD, et al., on behalf of the 056 Study Group. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med 2000 May 18; 342(20): 1484–91 Wolfrath SC, Borenstein AR, Schwartz S, et al. Use of nutritional supplements in Parkinson’s disease patients. Mov Disord 2006 Aug; 21(8): 1098–101 Sawabini KA, Evatt ML. Alternative therapy use in patients with cervical dystonia [abstract no. P226]. Mov Disord 2004; 19Suppl. 9: S90 Remple MS, Sarpong Y, Neimat JS. Frontiers in the surgical treatment of Parkinson’s disease. Expert Rev Neurother 2008 Jun; 8(6): 897–906 Uc EY, Follett KA. Deep brain stimulation in movement disorders. Semin Neurol 2007 Apr; 27(2): 170–82 Suchowersky O, Gronseth G, Perlmutter J, et al. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006 Apr 11; 66(7): 976–82 Barichella M, Marczewska A, De Notaris R, et al. Special low-protein foods ameliorate postprandial off in patients with advanced Parkinson’s disease. Mov Disord 2006 Oct; 21(10): 1682–7 Barichella M, Savardi C, Mauri A, et al. Diet with LPP for renal patients increases daily energy expenditure and improves motor function in parkinsonian patients with motor fluctuations. Nutr Neurosci 2007 Jun–Aug; 10(3–4): 129–35 de Lau LM, Bornebroek M, Witteman JC, et al. Dietary fatty acids and the risk of Parkinson disease: the Rotterdam study. Neurology 2005 Jun 28; 64(12): 2040–5 Vanitallie TB, Nonas C, Di Rocco A, et al. Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology 2005 Feb 22; 64(4): 728–30 Gao X, Chen H, Choi HK, et al. Diet, urate, and Parkinson’s disease risk in men. Am J Epidemiol 2008 Apr 1; 167(7): 831–8 Chen H, O’Reilly E, McCullough ML, et al. Consumption of dairy products and risk of Parkinson’s disease. Am J Epidemiol 2007 May 1; 165(9): 998–1006 Gao X, Chen H, Fung TT, et al. Prospective study of dietary pattern and risk of Parkinson disease. Am J Clin Nutr 2007 Nov; 86(5): 1486–94 Khor SP, Hsu A. The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson’s disease. Curr Clin Pharmacol 2007 Sep; 2(3): 234–43 Cooper MK, Brock DG, McDaniel CM. Interaction between levodopa and enteral nutrition. Ann Pharmacother 2008 Mar; 42(3): 439–42 Gillespie NG, Mena I, Cotzias GC, et al. Diets affecting treatment of parkinsonism with levodopa. J Am Diet Assoc 1973 May; 62(5): 525–8 Mena I, Cotzias GC. Protein intake and treatment of Parkinson’s disease with levodopa. N Engl J Med 1975 Jan 23; 292(4): 181–4 Pincus JH, Barry K. Influence of dietary protein on motor fluctuations in Parkinson’s disease. Arch Neurol 1987 Mar; 44(3): 270–2 Wolfe RR, Miller SL, Miller KB. Optimal protein intake in the elderly. Clin Nutr 2008 Oct; 27(5): 675–84 Gasior M, Rogawski MA, Hartman AL. Neuroprotective and disease-modifying effects of the ketogenic diet. Behav Pharmacol 2006 Sep; 17(5–6): 431–9 Ramaker C, Marinus J, Stiggelbout AM, et al. Systematic evaluation of rating scales for impairment and disability in Parkinson’s disease. Mov Disord 2002 Sep; 17(5): 867–76 Annanmaki T, Muuronen A, Murros K. Low plasma uric acid level in Parkinson’s disease. Mov Disord 2007 Jun 15; 22(8): 1133–7 Schlesinger I, Schlesinger N. Uric acid in Parkinson’s disease. Mov Disord 2008 Sep 15; 23(12): 1653–7 Newmark HL, Newmark J. Vitamin D and Parkinson’s disease: a hypothesis. Mov Disord 2007 Mar 15; 22(4): 461–8 Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967 May; 17(5): 427–42 Schwarzschild MA, Schwid SR, Marek K, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol 2008 Jun; 65(6): 716–23 Sofi F, Cesari F, Abbate R, et al. Adherence to Mediterranean diet and health status: meta-analysis. BMJ 2008; 337: a1344 Bender A, Koch W, Elstner M, et al. Creatine supple-mentation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 2006 Oct 10; 67(7): 1262–4 The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006 Mar 14; 66(5): 664–71 The NINDS NET-PD Investigators. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol 2008 May–Jun; 31(3): 141–50 Haas CT, Turbanski S, Kessler K, et al. The effects of random whole-body-vibration on motor symptoms in Parkinson’s disease. NeuroRehabilitation 2006; 21(1): 29–36 Di Rocco A, Rogers JD, Brown R, et al. S-Adenosylmethionine improves depression in patients with Parkinson’s disease in an open-label clinical trial. Mov Disord 2000 Nov; 15(6): 1225–9 Müller T, Fowler B, Kuhn W. Levodopa intake increases plasma levels of S-adenosylmethionine in treated patients with Parkinson disease. Clin Neuropharmacol 2005 Nov–Dec; 28(6): 274–6 Lamango NS, Nesby RA, Charlton CG. Quantification of S-adenosylmethionine-induced tremors: a possible tremor model for Parkinson’s disease. Pharmacol Biochem Behav 2000 Mar; 65(3): 523–9 Campbell RR, Hasinoff B, Chernenko G, et al. The effect of ferrous sulfate and pH on L-dopa absorption. Can J Physiol Pharmacol 1990 May; 68(5): 603–7 Etminan M, Gill SS, Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson’s disease: a meta-analysis. Lancet Neurol 2005 Jun; 4(6): 362–5 Chen H, Zhang SM, Schwarzschild MA, et al. Folate intake and risk of Parkinson’s disease. Am J Epidemiol 2004 Aug 15; 160(4): 368–75 de Lau LM, Koudstaal PJ, Witteman JC, et al. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology 2006 Jul 25; 67(2): 315–8 The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007 Jan 2; 68(1): 20–8 Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q (10) in Parkinson disease. Arch Neurol 2007 Jul; 64(7): 938–44 Hague T, Andrews PL, Barker J, et al. Dietary chelators as antioxidant enzyme mimetics: implications for dietary intervention in neurodegenerative diseases. Behav Pharmacol 2006 Sep; 17(5–6): 425–30 Hass CJ, Collins MA, Juncos JL. Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial. Neurorehabil Neural Repair 2007 Mar–Apr; 21(2): 107–15 Mesa JL, Ruiz JR, González-Gross MM, et al. Oral creatine supplementation and skeletal muscle metabolism in physical exercise. Sports Med 2002; 32(14): 903–44 Müller T, Woitalla D, Fowler B, et al. 3-OMD and homocysteine plasma levels in parkinsonian patients. J Neural Transm 2002 Feb; 109(2): 175–9 Trenkwalder C, Hening WA, Montagna P, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord 2008 Dec 15; 23(16): 2267–302 Gao X, Curhan G, Forman JP, et al. Vitamin C intake and serum uric acid concentration in men. J Rheumatol 2008 Sep; 35(9): 1853–8 Anderson C, Checkoway H, Franklin GM, et al. Dietary factors in Parkinson’s disease: the role of food groups and specific foods. Mov Disord 1999 Jan; 14(1): 21–7 Evatt ML, Delong MR, Khazai N, et al. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol 2008 Oct; 65(10): 1348–52 Sato Y, Kikuyama M, Oizumi K. High prevalence of vitamin D deficiency and reduced bone mass in Parkinson’s disease. Neurology 1997 Nov; 49(5): 1273–8 Sato Y, Manabe S, Kuno H, et al. Amelioration of osteopenia and hypovitaminosis D by 1alpha-hydroxyvitamin D3 in elderly patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999 Jan; 66(1): 64–8 Sato Y, Honda Y, Iwamoto J, et al. Abnormal bone and calcium metabolism in immobilized Parkinson’s disease patients. Mov Disord 2005 Dec; 20(12): 1598–603 Obeid R, McCaddon A, Herrmann W. The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric diseases. Clin Chem Lab Med 2007; 45(12): 1590–606 Qureshi GA, Qureshi AA, Devrajani BR, et al. Is the deficiency of vitamin B12 related to oxidative stress and neurotoxicity in Parkinson’s patients? CNS Neurol Disord Drug Targets 2008 Feb; 7(1): 20–7 Splaver A, Lamas GA, Hennekens CH. Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials. Am Heart J 2004 Jul; 148(1): 34–40 Lamberti P, Zoccolella S, Armenise E, et al. Hyperhomocysteinemia in L-dopa treated Parkinson’s disease patients: effect of cobalamin and folate administration. Eur J Neurol 2005 May; 12(5): 365–8 Postuma RB, Espay AJ, Zadikoff C, et al. Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: a randomized controlled study. Neurology 2006 Jun 27; 66(12): 1941–3 Zesiewicz TA, Wecker L, Sullivan KL, et al. The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status. Clin Neuropharmacol 2006 May–Jun; 29(3): 106–11 Zoccolella S, Iliceto G, deMari M, et al. Management of L-Dopa related hyperhomocysteinemia: catechol-O-methyltransferase (COMT) inhibitors or B vitamins? Results from a review. Clin Chem Lab Med 2007; 45(12): 1607–13 Jacques PF, Selhub J, Bostom AG, et al. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999 May 13; 340(19): 1449–54 Klawans HL, Ringel SP, Shenker DM. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor. J Neurol Neurosurg Psychiatry 1971 Dec; 34(6): 682–6 O’Suilleabhain PE, Sung V, Hernandez C, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004 Jun; 61(6): 865–8 Triantafyllou NI, Nikolaou C, Boufidou F, et al. Folate and vitamin B12 levels in levodopa-treated Parkinson’s disease patients: their relationship to clinical manifestations, mood and cognition. Parkinsonism Relat Disord 2008; 14(4): 321–5 Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002 Oct; 59(10): 1541–50 Elm JJ, Goetz CG, Ravina B, et al. A responsive outcome for Parkinson’s disease neuroprotection futility studies. Ann Neurol 2005 Feb; 57(2): 197–203 MedlinePlus. Coenzyme Q10 [online]. Available from URL: http://www.nlm.nih.gov/medlineplus/druginfo/natural/patient-coenzymeq10.html [Accessed 2009 Jun 16] Chung V, Liu L, Bian Z, et al. Efficacy and safety of herbal medicines for idiopathic Parkinson’s disease: a systematic review. Mov Disord 2006 Oct; 21(10): 1709–15 Katzenschlager R, Evans A, Manson A, et al. Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry 2004 Dec; 75(12): 1672–7 Sharma H, Chandola HM, Singh G, et al. Utilization of Ayurveda in health care: an approach for prevention, health promotion, and treatment of disease: II. Ayurveda in primary health care. J Altern Complement Med 2007 Dec; 13(10): 1135–50 Dhanasekaran M, Tharakan B, Manyam BV. Antiparkinson drug: Mucuna pruriens shows antioxidant and metal chelating activity. Phytother Res 2008 Jan; 22(1): 6–11 Deleu D, Jacob P, Chand P, et al. Effects of caffeine on levodopa pharmacokinetics and pharmacodynamics in Parkinson disease. Neurology 2006 Sep 12; 67(5): 897–9 Kitagawa M, Houzen H, Tashiro K. Effects of caffeine on the freezing of gait in Parkinson’s disease. Mov Disord 2007 Apr 15; 22(5): 710–2 Quik M, O’Leary K, Tanner CM. Nicotine and Parkinson’s disease: implications for therapy. Mov Disord 2008 Sep 15; 23(12): 1641–52 Villafane G, Cesaro P, Rialland A, et al. Chronic high dose transdermal nicotine in Parkinson’s disease: an open trial. Eur J Neurol 2007 Dec; 14(12): 1313–6 Simon DK, Swearingen CJ, Hauser RA, et al. Caffeine and progression of Parkinson disease. Clin Neuropharmacol 2008 Jul–Aug; 31(4): 189–96 Kandinov B, Giladi N, Korczyn AD. The effect of cigarette smoking, tea, and coffee consumption on the progression of Parkinson’s disease. Parkinsonism Relat Disord 2007 May; 13(4): 243–5 Goodwin VA, Richards SH, Taylor RS, et al. The effectiveness of exercise interventions for people with Parkinson’s disease: a systematic review and meta-analysis. Mov Disord 2008 Apr 15; 23(5): 631–40 Dibble LE, Hale TF, Marcus RL, et al. High-intensity resistance training amplifies muscle hypertrophy and functional gains in persons with Parkinson’s disease. Mov Disord 2006 Sep; 21(9): 1444–52 Falvo MJ, Schilling BK, Earhart GM. Parkinson’s disease and resistive exercise: rationale, review, and recommendations. Mov Disord 2008 Jan; 23(1): 1–11 Fisher BE, Wu AD, Salem GJ, et al. The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson’s disease. Arch Phys Med Rehabil 2008 Jul; 89(7): 1221–9 Klein PJ, Rivers L. Taiji for individuals with Parkinson disease and their support partners: a program evaluation. J Neurol Phys Ther 2006 Mar; 30(1): 22–7 Schmitz-Hübsch T, Pyfer D, Kielwein K, et al. Qigong exercise for the symptoms of Parkinson’s disease: a randomized, controlled pilot study. Mov Disord 2006 Apr; 21(4): 543–8 Burini D, Farabollini B, Iacucci S, et al. A randomised controlled cross-over trial of aerobic training versus Qigong in advanced Parkinson’s disease. Eura Medicophys 2006 Sep; 42(3): 231–8 Ashburn A, Fazakarley L, Ballinger C, et al. A randomised controlled trial of a home based exercise programme to reduce the risk of falling among people with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2007 Jul; 78(7): 678–84 Caglar AT, Gurses HN, Mutluay FK, et al. Effects of home exercises on motor performance in patients with Parkinson’s disease. Clin Rehabil 2005 Dec; 19(8): 870–7 Lun V, Pullan N, Labelle N, et al. Comparison of the effects of a self-supervised home exercise program with a physiotherapist-supervised exercise program on the motor symptoms of Parkinson’s disease. Mov Disord 2005 Aug; 20(8): 971–5 Farley BG, Koshland GF. Training BIG to move faster: the application of the speed-amplitude relation as a rehabilitation strategy for people with Parkinson’s disease. Exp Brain Res 2005 Dec; 167(3): 462–7 Protas EJ, Mitchell K, Williams A, et al. Gait and step training to reduce falls in Parkinson’s disease. Neuro-Rehabilitation 2005; 20(3): 183–90 Brichetto G, Pelosin E, Marchese R, et al. Evaluation of physical therapy in parkinsonian patients with freezing of gait: a pilot study. Clin Rehabil 2006 Jan; 20(1): 31–5 Ellis T, de Goede CJ, Feldman RG, et al. Efficacy of a physical therapy program in patients with Parkinson’s disease: a randomized controlled trial. Arch Phys Med Rehabil 2005 Apr; 86(4): 626–32 del Olmo MF, Cudeiro J. Temporal variability of gait in Parkinson disease: effects of a rehabilitation programme based on rhythmic sound cues. Parkinsonism Relat Disord 2005 Jan; 11(1): 25–33 del Olmo MF, Arias P, Furio MC, et al. Evaluation of the effect of training using auditory stimulation on rhythmic movement in parkinsonian patients: a combined motor and [18F]-FDG PET study. Parkinsonism Relat Disord 2006 Apr; 12(3): 155–64 Hausdorff JM, Lowenthal J, Herman T, et al. Rhythmic auditory stimulation modulates gait variability in Parkinson’s disease. Eur J Neurosci 2007 Oct; 26(8): 2369–75 Rochester L, Nieuwboer A, Baker K, et al. The attentional cost of external rhythmical cues and their impact on gait in Parkinson’s disease: effect of cue modality and task complexity. J Neural Transm 2007; 114(10): 1243–8 van Wegen E, Lim I, de Goede C, et al. The effects of visual rhythms and optic flow on stride patterns of patients with Parkinson’s disease. Parkinsonism Relat Disord 2006 Jan; 12(1): 21–7 Tamir R, Dickstein R, Huberman M. Integration of motor imagery and physical practice in group treatment applied to subjects with Parkinson’s disease. Neurorehabil Neural Repair 2007 Jan–Feb; 21(1): 68–75 Turbanski S, Haas CT, Schmidtbleicher D, et al. Effects of random whole-body vibration on postural control in Parkinson’s disease. Res Sports Med 2005 Jul–Sep; 13(3): 243–56 Ebersbach G, Edler D, Kaufhold O, et al. Whole body vibration versus conventional physiotherapy to improve balance and gait in Parkinson’s disease. Arch Phys Med Rehabil 2008 Mar; 89(3): 399–403 Comella CL, Stebbins GT, Brown-Toms N, et al. Physical therapy and Parkinson’s disease: a controlled clinical trial. Neurology 1994 Mar; 44 (3 Pt 1): 376–8 Watts JJ, McGinley J, Huxham F, et al. Cost effectiveness of preventing falls and improving mobility in people with Parkinson disease: protocol for an economic evaluation alongside a clinical trial. BMC Geriatr 2008 Sep 30; 8(1): 23–30 Paterson C, Allen JA, Browning M, et al. A pilot study of therapeutic massage for people with Parkinson’s disease: the added value of user involvement. Complement Ther Clin Pract 2005 Aug; 11(3): 161–71 Svircev A, Craig LH, Juncos JL. A pilot study examining the effects of neuromuscular therapy on patients with Parkinson’s disease [abstract]. J Am Osteopath Assoc 2005 Jan; 105(1): 26 Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, et al. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson’s disease: a randomized, double blind, placebo-controlled study. J Neurol 2007 Apr; 254(4): 459–64 Dowling GA, Mastick J, Colling E, et al. Melatonin for sleep disturbances in Parkinson’s disease. Sleep Med 2005 Sep; 6(5): 459–66 Paus S, Schmitz-Hübsch T, Wüllner U, et al. Bright light therapy in Parkinson’s disease: a pilot study. Mov Disord 2007 Jul 30; 22(10): 1495–8 Willis GL, Turner EJ. Primary and secondary features of Parkinson’s disease improve with strategic exposure to bright light: a case series study. Chronobiol Int 2007; 24(3): 521–37 Eng ML, Lyons KE, Greene MS, et al. Open-label trial regarding the use of acupuncture and yin tui na in Parkinson’s disease outpatients: a pilot study on efficacy, tolerability, and quality of life. J Altern Complement Med 2006 May; 12(4): 395–9 Cristian A, Katz M, Cutrone E, et al. Evaluation of acupuncture in the treatment of Parkinson’s disease: a double-blind pilot study. Mov Disord 2005 Sep; 20(9): 1185–8 Trinh K, Graham N, Gross A, et al. Acupuncture for neck disorders. Spine 2007 Jan 15; 32(2): 236–43 Inzelberg R, Peleg N, Nisipeanu P, et al. Inspiratory muscle training and the perception of dyspnea in Parkinson’s disease. Can J Neurol Sci 2005 May; 32(2): 213–7 Silverman EP, Sapienza CM, Saleem A, et al. Tutorial on maximum inspiratory and expiratory mouth pressures in individuals with idiopathic Parkinson disease (IPD) and the preliminary results of an expiratory muscle strength training program. NeuroRehabilitation 2006; 21(1): 71–9 Deane KH, Whurr R, Playford ED, et al. Speech and language therapy for dysarthria in Parkinson’s disease. Cochrane Database Syst Rev 2001; (2): CD002812 Deane KH, Whurr R, Playford ED, et al. A comparison of speech and language therapy techniques for dysarthria in Parkinson’s disease. Cochrane Database Syst Rev 2001; (2): CD002814 Sapir S, Spielman JL, Ramig LO, et al. Effects of intensive voice treatment (the Lee Silverman Voice Treatment [LSVT]) on vowel articulation in dysarthric individuals with idiopathic Parkinson disease: acoustic and perceptual findings. J Speech Lang Hear Res 2007 Aug; 50(4): 899–912 Sturtzel B, Elmadfa I. Intervention with dietary fiber to treat constipation and reduce laxative use in residents of nursing homes. Ann Nutr Metab 2008; 52 Suppl. 1: 54–6 Astarloa R, Mena MA, Sánchez V, et al. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol 1992 Oct; 15(5): 375–80 El Sharkawi A, Ramig L, Logemann JA, et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study. J Neurol Neurosurg Psychiatry 2002 Jan; 72(1): 31–6 Sunagane N, Aikawa M, Ohta T, et al. Possibility of interactions between prescription drugs and OTC drugs (2nd report): interaction between levodopa preparation and OTC Kampo medicines for upset stomach. Yakugaku Zasshi 2006 Nov; 126(11): 1191–6 Rodrigues de Paula F, Teixeira-Salmela LF, Coelho de Morais Faria CD, et al. Impact of an exercise program on physical, emotional, and social aspects of quality of life of individuals with Parkinson’s disease. Mov Disord 2006 Aug; 21(8): 1073–7 Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. Drugs 2005; 65(9): 1239–82 Lahrmann H, Cortelli P, Hilz M, et al. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol 2006 Sep; 13(9): 930–6 Schoffer KL, Henderson RD, O’Maley K, et al. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson’s disease. Mov Disord 2007 Aug 15; 22(11): 1543–9 Deane KH, Ellis-Hill C, Jones D, et al. Systematic review of paramedical therapies for Parkinson’s disease. Mov Disord 2002 Sep; 17(5): 984–91 Verbaan D, Marinus J, Visser M, et al. Patient-reported autonomic symptoms in Parkinson disease. Neurology 2007 Jul 24; 69(4): 333–41 Visser M, Marinus J, van Hilten JJ, et al. Assessing comorbidity in patients with Parkinson’s disease. Mov Disord 2004 Jul; 19(7): 824–8 Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson’s disease. Parkinsonism Relat Disord 2007 Sep; 13 Suppl.: S2–7 Lorefät B, Ganowiak W, Wissing U, et al. Food habits and intake of nutrients in elderly patients with Parkinson’s disease. Gerontology 2006; 52(3): 160–8 Chen H, Zhang SM, Hernán MA, et al. Weight loss in Parkinson’s disease. Ann Neurol 2003 May; 53(5): 676–9 Deane KH, Whurr R, Clarke CE, et al. Non-pharmacological therapies for dysphagia in Parkinson’s disease. Cochrane Database Syst Rev 2001; (1): CD002816 Senard JM, Brefel-Courbon C, Rascol O, et al. Orthostatic hypotension in patients with Parkinson’s disease: pathophysiology and management. Drugs Aging 2001; 18(7): 495–505 Martínez-Martín P, Tolosa E, Hernández B, et al. The patient card questionnaire to identify wearing-off in Parkinson disease. Clin Neuropharmacol 2007 Sep–Oct; 30(5): 266–75 Santens P, de Noordhout AM, for the Belgian EODWO Study Group. Detection of motor and non-motor symptoms of end-of dose wearing-off in Parkinson’s disease using a dedicated questionnaire: a Belgian multicenter survey. Acta Neurol Belg 2006 Sep; 106(3): 137–41 Stacy MA, Murphy JM, Greeley DR, et al. The sensitivity and specificity of the 9-item wearing-off questionnaire. Parkinsonism Relat Disord 2008; 14(3): 205–12